Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-s

[News]

Roche/Genentech/Chugai's pertuzumab plus trastuzumab (Roche/Genentech/Chugai's Herceptin) and docetaxel (Sanofi's Taxotere, generics) will become Decision Resources' proprietary clinical gold-standard treatment for metastatic first-line HER2-positive breast cancer in 2015.

More... (http://www.news-medical.net/news/20120203/Pertuzumab-plus-trastuzumab-and-docetaxel-has-advantages-over-current-clinical-gold-standard-treatment.aspx)